Kanseri y'ibere ni yo kanseri igira kabiri mu zikunda gufata abagabo kw'isi yose, hakaba haharurwa ko mu 2018 hari abantu bashasha 1.276 bayanduye, ni ukuvuga ibice 7,1% vy'abagabo bose barwaye kanseri.
Imibare y'abahitanwa na kanseri ya prostate na yo nyene ni myinshi, aho mu 2018 abantu bashika 37.005 bapfuye kw'isi yose.
Ariko rero, urugero rw'abahitanwa na kanseri y'ibere ruratandukanye cane bivanye n'akarere, muri Afrika y'uburengero akaba ari ho hari abantu benshi cane bahitanwa na kanseri y'ibere kw'isi, muri Nijeriya na ho hakaba ari ho hari abantu benshi cane kandi ubutunzi bwaho bukaba ari bwo bwa mbere mu bunini.
Muri Nijeriya, kanseri y'uruti rw'umugongo ni yo kanseri ikunda gufata abagabo kandi ihitana benshi, hakaba haharurwa ko ku bagabo 100.000 hapfa abagera kuri 32,8 n'abapfa 16,3.
Ni incuro zirenga zibiri urugero rw'abapfa muri Amerika yo mu Buraruko.
Kuba iyo ndwara imenyekana hakiri kare, kuba ata buryo buhagije bwo kuyisuzuma no kuyirondera buhari, be no kuba abantu bake ari bo bandika bakongera bakamenyesha ko bayirwaye, biri mu bituma muri Nijeriya abantu benshi bapfa.
Muri Leta Zunze Ubumwe za Amerika, kanseri y'uruti rw'umugongo ni yo iza ubwa kabiri mu ndwara zica abagabo benshi, aho ku mwaka hapfa abagabo nka 40.000.
Naho igitigiri c'abahitanwa na kanseri y'ibere kiguma kigabanuka kuva mu ntango z'imyaka ya 1990, iyo ndwara irabandanya gutera ingorane zikomeye z'amagara y'abantu.
Muri rusangi, kanseri y'ibere ni indwara yica, canecane mu turere usanga abantu bataronka uburyo buhagije bwo kwivuza no kwipimisha.
Ariko rero, iyo umuntu ayisuzumye hakiri kare kandi akayivura, birashobora gutuma arushiriza kumererwa neza no gutuma abantu bapfa bagabanuka.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Urupapuro rwemeza ko ata ruhusha:']
["Uru rubuga rw'ivy'ubuvuzi ruratangwa ku bw'inyigisho no ku bw'ukumenyesha amakuru gusa, ntirutanga impanuro mu vy'ubuvuzi canke ngo rube urwego rw'abahinga mu vy'ubuvuzi."]
["Itegeko ryo mu 1998 ryerekeye uburenganzira umuntu afise mu vyo akoresha mu guhanahana amakuru (Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) ritanga uburenganzira ku bantu bafise uburenganzira bwo guhanahana amakuru babona ko ibintu vyerekanwa kuri Internet bihonyanga uburenganzira bwabo hisunzwe amategeko ya Leta Zunze Ubumwe za Amerika ajanye n'uburenganzira umuntu afise. "]
['Mu gihe wibaza ko hari ibintu canke ibikoresho vyabonetse ku rubuga rwacu canke ku mbuga zacu bibangamiye uburenganzira bwawe, wewe (canke uwukugenzura) urashobora kuturungikira ubutumwa busaba ko ivyo bintu canke ivyo bikoresho bikurwaho canke ko bitagisubira kuboneka. ']
['Amatangazo ategerezwa kurungikwa mu nyandiko hakoreshejwe ubutumwa bwa "email" (raba ahavuga ngo "Kwitaba" kugira ngo umenye aderese ya "email").']
["Itegeko rya DMCA risaba ko umenyesha ko hari uwugomba guhonyanga uburenganzira bwawe mu gutanga amakuru akurikira: (1) idondorwa ry'igikorwa gikingiwe n'amategeko kiriko kiragirizwa guhonyanga uburenganzira bwawe; (2) idondorwa ry'ibiri mu vyo bavuga ko bihonyanga uburenganzira bwawe be n'amakuru ahagije atuma dushobora kumenya aho biri; (3) amakuru y'ukuntu twokwifatanya nawe, harimwo aderese yawe, inomero za telefone n'ikete ryawe ryo kurungikiranira ubutumwa kuri internet; (4) ivyemeza ko wemera udakeka ko ivyo bintu biri mu buryo uriko uridodombera bitahawe uburenganzira n'uwabitunganije, canke uwubiserukira, canke n'itegeko iryo ari ryo ryose; "]
["(5) urwandiko rwanditswe n'uwatanze iyo notifica-tion, rwemeza ko amakuru ari muri iyo notifica-tion ari ay'ukuri kandi ko afise ububasha bwo gukurikirana ivy'uwo muntu avuga ko yahonyanze uburenganzira bwiwe; "]
['Turakwinginze uturungikire ubutumwa kuri email ufise ikibazo / iciyumviro.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
